1080mg modified release tablets

Prescribing Information Renodyra 1080 mg modified-release tablets

For the treatment of adult patients with kidney stones and hypocitraturia or chronic calcium oxalate stones, prevention and treatment of recurrent uric acid lithiasis with or without calcium lithiasis and cysteine lithiasis and treatment of renal tubular acidosis with calcium nephrolithiasis. The tablets should be taken orally with meals or within 30 minutes after meals up to three times a day in divided doses. Dosing is based upon severity and starts from 3240mg per day up to 10800mg maximum dose. Do not use: If hypersensitivity to the active substance or to any of the excipients, renal impairment, active or persistent urinary tract infections, significant or complete obstruction of the urinary tract, hyperkalaemia, severe myocardial injury, uncontrolled diabetes mellitus, adrenal insufficiency, metabolic or respiratory alkalosis, active peptic ulcer, delayed gastric emptying or intestinal obstruction. This medicine should be used with caution when combined with other products that increase plasma potassium or predispose to cardiac arrest and regular monitoring of renal function parameters and blood potassium levels is recommended every 4 months. In patients with severe renal function, regular monitoring at least twice a year is required. Common side effects include abdominal pain, nausea, diarrhoea, gaseousness, dyspepsia, oesophagitis, dysphagia and skin rash. Serious adverse reaction such as hyperkalaemia may lead to muscle weakness/paralysis, cardiac conduction abnormalities and cardiac arrhythmia. Prescribers should consult the summary of product characteristics for further information. The product is packed in a polyethylene (HDPE) bottle, closed with a tamper evident cap with an aluminium PE / PP / Al insert. Legal category: POM PL56328/0002 MAH: Penlan Pharmaceuticals Ltd, 45-47 Monument Hill, Weybridge, KT13 8RN. Price: £62.04 Revised: December 2025. UK/100036/013 v2.0 December 2025